Pfizer Veteran Bernard Fermini Joins Novoheart as Chief R&D Officer

Novoheart (TSXV: [[ticker:NVH]]) has appointed Bernard Fermini to serve as chief research and development officer of the Vancouver, BC, stem cell biotechnology company. Fermini most recently worked at Coyne Scientific, where he was vice president of safety and toxicology and chief scientific officer. His experience also includes 17 years at Pfizer (NYSE: [[ticker:PFE]]), where he held various positions including co-chair of the company’s global safety pharmacology department. NovoHeart is developing a “human heart in a jar,” a human heart tissue prototype intended for applications in drug research.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan